These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 3937254)

  • 1. [Anti-HTLV-III antibodies in hemophiliacs treated with concentrates of factors VIII or IX].
    Aznar JA; Granda D; Jorquera J; González-Molina A; Carmona E; Peiró A; Gobernado M
    Sangre (Barc); 1985; 30(5):934-5. PubMed ID: 3937254
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlation of antibodies to LAV/HTLV III in hemophiliacs with the use of virus-inactivated clotting factors.
    Dietz B; Klose HJ; Gürtler L; Eberle J; Deinhardt F; Köhler-Vajta K; Peller P
    Thromb Haemost; 1986 Aug; 56(1):50-2. PubMed ID: 3095947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HTLV-III antibodies and immunologic changes in hemophilic children. Prevalence of HTLV-III antibodies in hemophilic children and their relatives living in the same household].
    Zenz W; Muntean W; Teubl I; Beaufort F; Heinz FX
    Padiatr Padol; 1987; 22(1):33-41. PubMed ID: 3108827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of antibodies to HTLV-I and -III in sera from Japanese hemophiliacs.
    Abe T; Kinoshita T; Matsuda J; Ryu T; Ting RC; Aoki T; Robert-Guroff M; Miyakoshi H; Gallo RC
    Cancer Res; 1985 Sep; 45(9 Suppl):4621s-4623s. PubMed ID: 2990696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, immunological, and virological aspects in Japanese hemophiliacs and AIDS patients.
    Abe T
    AIDS Res; 1986 Dec; 2 Suppl 1():S141-6. PubMed ID: 3103637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAV/HTLV-III seroconversion and disease in hemophiliacs treated in France.
    Mathez D; Leibovitch J; Sultan Y; Maisonneuve P
    N Engl J Med; 1986 Jan; 314(2):118-9. PubMed ID: 3079879
    [No Abstract]   [Full Text] [Related]  

  • 7. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
    Heimburger N; Karges HE; Weidmann E
    Dev Biol Stand; 1987; 67():303-10. PubMed ID: 3038638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of HTLV-III/LAV antibodies in Italian asymptomatic hemophiliacs given commercial concentrates of factors VIII and IX.
    Verani P; Mariani G; Mannucci PM; De Rossi G; Nicoletti L; Titti F; Falcione E; Pasqualetti D; Ammassari M; Gringeri A
    J Med Virol; 1986 Jun; 19(2):143-9. PubMed ID: 3014059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevalence of inhibitors in hemophiliacs with reference to the transfusion of blood products (author's transl)].
    Kamiya T
    Rinsho Byori; 1978; 26(4):291-7. PubMed ID: 671775
    [No Abstract]   [Full Text] [Related]  

  • 10. [Systematic detection of anti-LAV/HTLV-III antibodies in blood donors and hemophiliacs].
    Muncunill J; Forteza A; Forner N; Forteza-Rei J
    Med Clin (Barc); 1986 Apr; 86(13):565. PubMed ID: 3012224
    [No Abstract]   [Full Text] [Related]  

  • 11. Overview of inhibitors to factor VIII and IX.
    Roberts HR; Cromartie R
    Prog Clin Biol Res; 1984; 150():1-18. PubMed ID: 6431420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of anti-HTLV-III antibodies in hemophiliacs--prevalence rates in Japan and comparison of two assay systems].
    Hattori T; Shojiro I; Uchida T; Matsuoka M; Yamamoto S; Hiyoshi Y; Fukutake K; Takatsuki K
    Rinsho Ketsueki; 1986 Jul; 27(7):1057-63. PubMed ID: 3465965
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
    Rup B
    Dev Biol (Basel); 2003; 112():55-9. PubMed ID: 12762504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies reactive with human T cell leukemia viruses in the serum of hemophiliacs receiving factor VIII concentrate.
    Goedert JJ; Sarngadharan MG; Eyster ME; Weiss SH; Bodner AJ; Gallo RC; Blattner WA
    Blood; 1985 Feb; 65(2):492-5. PubMed ID: 2981592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical studies with treated clotting factor concentrates.
    Colombo M; Mannucci PM
    Dev Biol Stand; 1987; 67():333-6. PubMed ID: 3038639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Factor VIII and IX inhibitors].
    Nagao T; Iizuka A
    Rinsho Byori; 1987 Apr; Spec No 70():255-65. PubMed ID: 3112447
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 19. [Penetration of anti-LVA/HTLV-III in type A and B hemophiliacs. Clinical and immunologic follow-up].
    Ollero M; Leal M; Ramsey R; Wichman I; Vinuesa M; Muñoz J; Palmer E; Lissen E
    Med Clin (Barc); 1986 Jan; 86(3):100-4. PubMed ID: 3485746
    [No Abstract]   [Full Text] [Related]  

  • 20. New alternatives and strategies in the treatment of inhibitors.
    Hoyer LW
    Prog Clin Biol Res; 1984; 150():367-72. PubMed ID: 6431440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.